AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1991923
Drug: IgE antibody
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgE antibody specific for formaldehyde-human serum albumin detected by ELISA in three subjects.
Trial: 6109741
Drug: Chlorpheniramine 8
RxNorm normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 8 mg (single dose)
Trial: 6109741
Drug: Chlorpheniramine 8
RxNorm normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 8 mg (seven doses)
Trial: 6109741
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg (single dose)
Trial: 6109741
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg (seven doses)
Trial: 6109741
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chlorpheniramine and cimetidine (seven doses)
Trial: 26596670
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus lenalidomide (six cycles of cyclophosphamide [300 mg/m2, days 1, 8, and 15], dexamethasone [40 mg, days 1, 8, 15, and 22], and lenalidomide [25 mg, days 1-21])
Trial: 26596670
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan (200 mg/m2) and ASCT
Trial: 26596670
Drug: Lenalidomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (10 mg, days 1-21) plus prednisone (50 mg, every other day)
Trial: 26596670
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus lenalidomide
Trial: 9215300
Drug: 0.1 mU.kg‐1.min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mU.kg‐1.min‐1 euglycemic insulin clamp
Trial: 9215300
Drug: 0.4 mU.kg‐1.min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mU.kg‐1.min‐1 euglycemic insulin clamp
Trial: 9215300
Drug: iv 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv 0.9% NaCl infusion after oral acipimox administration (250 mg)
Trial: 8573453
Drug: Chemopreventive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemopreventive agents such as retinoids and tamoxifen
Trial: 2223687
Drug: Norethisterone acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate, 1 mg (group A)
Trial: 2223687
Drug: Norethisterone acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate, 0.5 mg (group B)
Trial: 2223687
Drug: Megestrol acetate,
RxNorm normalized name: megestrol acetate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol acetate, 5 mg (group C)
Trial: 2223687
Drug: Megestrol acetate,
RxNorm normalized name: megestrol acetate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol acetate, 2.5 mg (group D)
Trial: 573602
Drug: Kallikrein (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kallikrein (600 units porcine pancreatic kallikrein daily for 7 weeks)
Trial: 573602
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 7 weeks)
Trial: 26801909
Drug: Artemisinin combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin combination therapy (ACT)
Trial: 21947320
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day plus modafinil 200 mg/day
Trial: 17156104
Drug: Sitagliptin 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 5, 12.5, 25 or 50 mg b.i.d.
Trial: 17156104
Drug: Glipizide 5
RxNorm normalized name: glipizide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide 5 mg/day (titrated up to 20 mg/day)
Trial: 8372418
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of immunosuppressants in adults
Trial: 8372418
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of immunosuppressants in children
Trial: 20068423
Drug: Maintenance training
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance training (MT) for 1 year, including weekly supervised training for the first 6 months, bi-weekly supervised training for the next 6 months, and no supervised training for the last 6 months.
Trial: 7489965
Drug: Recombinant interferon‐alfa2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alfa2b 5 MU/m2 thrice weekly for 4 months, continued up to 12 months if ALT reduced by at least 50%
Trial: 1683682
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b polysaccharide (PRP) vaccine
Trial: 1683682
Drug: Polysaccharide‐mutant diphtheria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide‐mutant diphtheria toxoid conjugate vaccine (PRP‐CRM)
Trial: 31894038
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Trial: 31894038
Drug: Parenteral nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutritional support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Trial: 27052036
Drug: Melatonin cream
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin cream 12.5% applied on 80% of body surface area
Trial: 22250853
Drug: Positive response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Positive response to MDD treatment
Trial: 22250853
Drug: Initial MDD
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial MDD treatment (CBT, FLX, COMB, PBO)
Trial: 22250853
Drug: Prior involvement
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior involvement with alcohol or drugs
Trial: 11769996
Drug: Prednisone tablets
RxNorm normalized name: Prednisone Tablets
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone tablets
Trial: 2503490
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg, orally)
Trial: 28120497
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg (with optional uptitration to 300 mg)
Trial: 29911577
Drug: Experimental knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental knee pain (hypertonic saline injection)
Trial: 29911577
Drug: Control (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isotonic saline injection)
Trial: 21227540
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg intravenous metoclopramide
Trial: 18306984
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment with pantoprazole (40 mg twice daily), amoxicillin (1000 mg twice daily), and clarithromycin (500 mg) for 7 days
Trial: 18306984
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment with ranitidine bismuth citrate (400 mg twice daily), metronidazole (250 mg twice daily), and clarithromycin (500 mg) for 7 days
Trial: 18306984
Drug: Third-line quadruple
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-line quadruple therapies with pantoprazole + amoxicillin and tetracycline (500 mg four times daily) and either nitrofurantoin (100 mg three times daily) or bismuth subsalicylate (120 mg four times daily)
Trial: 11058672
Drug: Inhaled zanamivir
RxNorm normalized name: zanamivir Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled zanamivir (10 mg twice a day for 5 days for index cases, 10 mg once a day for 10 days for family members)
Trial: 3914703
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg/qd
Trial: 31251548
Drug: Kamedis Eczema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kamedis Eczema Therapy Cream (tested product)
Trial: 28918674
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Fruitflow®
Trial: 25284142
Drug: High-dose proton-pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose proton-pump inhibitors (HD PPIs)
Trial: 22409309
Drug: Eltrombopag (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (12.5 mg)
Trial: 20174834
Drug: landiolol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: landiolol 0.1 mg/kg
Trial: 20174834
Drug: nicardipine 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nicardipine 0.02 mg/kg
Trial: 16018750
Drug: Vitamin-B complex
RxNorm normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin-B complex supplementation (50 mg of thiamine HCl, riboflavin, niacinamide, d-calcium pantothenate, pyridoxine HCl; 50 microg each of d-biotin and cyanocobalamin; and 400 mcg of folate) for 30 days after AFS
Trial: 12454519
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (Group B)
Trial: 7499110
Drug: Sulofenur 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulofenur 640 mg/M2
Trial: 7499110
Drug: Sulofenur 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulofenur 800 mg/M2
Trial: 7499110
Drug: Sulofenur 960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulofenur 960 mg/M2
Trial: 1959341
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CaCO3) 6 g/day for 3 months
Trial: 6765542
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin combination with 20% regular and 80% NPH
Trial: 6765542
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin combination with 30% regular and 70% NPH
Trial: 6765542
Drug: PPI 30/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI 30/70 combination
Trial: 31600414
Drug: Internet-delivered mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered mindfulness-based cognitive therapy (iMBCT)
Trial: 31119881
Drug: Daily self-weighing
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-weighing (DSW) with visual graphical feedback (GF)
Trial: 16395260
Drug: FK352 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK352 (50 mg, intravenous)
Trial: 9008601
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections at the same time frequency
Trial: 8497357
Drug: Standard skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard skin preparation plus normal saline irrigation
Trial: 8497357
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation plus antibiotic irrigation
Trial: 8497357
Drug: Special preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special preparation plus normal saline irrigation
Trial: 8497357
Drug: Special preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special preparation plus antibiotic irrigation
Trial: 28660739
Drug: 12 SQ
RxNorm normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 SQ HDM sublingual immunotherapy tablet
Trial: 25694217
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg/day) for 6 weeks
Trial: 23775581
Drug: Deferasirox (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (mean dose 9.8 ± 3.6 mg/kg/day)
Trial: 23775581
Drug: Deferasirox (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (mean dose in extension 13.7 ± 4.6 mg/kg/day)
Trial: 16575712
Drug: Medical Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Training Therapy (MTT)
Trial: 11851735
Drug: Spasticity management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spasticity management (intramuscular injections of phenol, alcohol, and botulinum toxin type A)
Trial: 9517912
Drug: Milnacipran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (50 mg twice daily)
Trial: 9517912
Drug: Imipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50 mg twice daily)
Trial: 22713081
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine (CHX) gel and 304% fluoride toothpaste
Trial: 22713081
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (twice daily toothbrushing with toothpaste only)
Trial: 18971385
Drug: Only conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only conventional therapy (control group)
Trial: 18971385
Drug: Only FES
RxNorm normalized name: Product containing only fesoterodine (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only FES therapy (chronic group)
Trial: 9496386
Drug: Epirubicin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin monotherapy every two weeks (110 mg/m2) with filgrastim (5 micrograms/kg/daily) prophylactically on days 2‐12 of each cycle
Trial: 9496386
Drug: Epirubicin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin monotherapy every four weeks (110 mg/m2) with filgrastim (5 micrograms/kg/daily) prophylactically on days 2‐12 of each cycle
Trial: 9496386
Drug: Epirubicin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin monotherapy every two weeks
Trial: 9496386
Drug: Epirubicin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin monotherapy every four weeks
Trial: 8369939
Drug: Single-dose cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cefuroxime (1.5 g intravenously before operation)
Trial: 8369939
Drug: Three-dose cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose cefuroxime regimen (1.5 g before and two doses of 0.75 g after operation)
Trial: 20090676
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg oral dosing)
Trial: 20090676
Drug: Erythromycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (125 mg intravenous dosing)
Trial: 12800418
Drug: Jiawei Mojie
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jiawei Mojie Tablet (JMT)
Trial: 11249645
Drug: MFG‐IRAP gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFG‐IRAP gene therapy
Trial: 8888384
Drug: Flesinoxan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flesinoxan (up to 2.4 mg per day)
Trial: 8888384
Drug: Flesinoxan (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flesinoxan (0.6 or 1.2 mg/day)
Trial: 1804665
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 40 mg.day-1
Trial: 1804665
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate 500 micrograms t.d.s.
Trial: 6358156
Drug: Irradiation combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation combined with misonidazole (1 gr/m2, total dose 12 gr/m2)
Trial: 26952645
Drug: Internet Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet Cognitive Behavioral Therapy (MumMoodBooster program)
Trial: 21044434
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) in combination with other DMARDs (e.g., leflunomide, cyclosporine, azathioprine, sulfasalazine, gold, hydroxychloroquine)
Trial: 21044434
Drug: Early use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early use of biologics
Trial: 11916808
Drug: S(+)‐ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine (0.5 mg/kg bolus before incision, followed by 2 microg x kg(‐1) x min(‐1) infusion until 2 h after emergence from anesthesia)
Trial: 1549961
Drug: Alendronate, 10
RxNorm normalized name: Alendronate, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 10 mg/day for 5 days
Trial: 19050436
Drug: Intraarterial autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial autologous BMCs with oral antioxidants and L-arginine
Trial: 19050436
Drug: Maximal drug
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal drug therapy (control group)
Trial: 12934760
Drug: Walnut oil
RxNorm normalized name: Walnut oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut oil (3 g/day in 500 mg capsules) for 45 days
Trial: 10651694
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course therapy (multiple courses of 12 weeks)
Trial: 10651694
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (1 year)
Trial: 10651694
Drug: Both short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both short course and continuous therapy
Trial: 8880657
Drug: Interactional couples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactional couples therapy
Trial: 8880657
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatments (BMT, interactional therapy, individual counseling)
Trial: 1668960
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acyclovir t.d. for 6 months
Trial: 27973619
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg/d
Trial: 25352484
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy after intravenous r‐tPA
Trial: 25352484
Drug: Intravenous r‐tPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous r‐tPA alone
Trial: 9065316
Drug: Tramazoline aerosol
RxNorm normalized name: tramazoline
DrugBank: Tramazoline (DB13064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramazoline aerosol (Rhinospray) 0.14 mg
Trial: 9065316
Drug: Tramazoline aerosol
RxNorm normalized name: tramazoline
DrugBank: Tramazoline (DB13064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramazoline aerosol (Rhinospray) 0.19 mg
Trial: 1683882
Drug: Noberastine (NOB)
RxNorm normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noberastine (NOB) 10 mg
Trial: 1683882
Drug: Noberastine (NOB)
RxNorm normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noberastine (NOB) 20 mg
Trial: 1683882
Drug: Noberastine (NOB)
RxNorm normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noberastine (NOB) 30 mg
Trial: 1683882
Drug: Noberastine (NOB)
RxNorm normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noberastine (NOB) 10, 20, and 30 mg
Trial: 31077168
Drug: Telephone cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone cognitive behavioural therapy (tCBT)
Trial: 22282432
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravenous psilocybin
Trial: 14526453
Drug: nCPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP therapy
Trial: 14526453
Drug: No nCPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nCPAP therapy (untreated group)
Trial: 10898689
Drug: Stavudine 40
RxNorm normalized name: stavudine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 40 mg single dose in subjects with mild renal impairment (CL(CR) 60 to 80)
Trial: 10898689
Drug: Stavudine 40
RxNorm normalized name: stavudine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 40 mg single dose in subjects with moderate renal impairment (CL(CR) 30 to 50)
Trial: 10898689
Drug: Stavudine 40
RxNorm normalized name: stavudine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 40 mg single dose in subjects with severe renal impairment (CL(CR) </=20)
Trial: 10898689
Drug: Stavudine dosage
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine dosage recommendations for renal impairment (for subjects weighing >/=60 kg)